人工智能用于前列腺穿刺活检诊断与分级:基于人群的诊断研究
该研究基于瑞典STHLM3人群诊断研究,数字化6682张穿刺活检切片训练深度神经网络,并在独立测试集(246人1631张)和外部验证集(73人330张)评估AI对前列腺癌检测、定位和Gleason分级的效能。AI区分良恶性活检核心的AUC在测试集为0·997,外部验证集为0·986;预测癌长度与实际报告长度的相关性分别为0·96和0·87;Gleason分级平均成对kappa为0·62,与23位国际泌尿病理学家的范围(0·60-0·73)相当。
要点
- AI检测前列腺癌的AUC在独立测试集达0·997,外部验证集0·986。
- AI预测癌长度与病理医生报告值的相关性在测试集为0·96,外部验证集0·87。
- AI的Gleason分级kappa为0·62,与专家病理学家范围(0·60-0·73)相当。
核心结论
- AI系统可被训练用于前列腺穿刺活检的癌症检测和分级,其效能与国际前列腺病理专家相当。
研究设计与样本
- 基于瑞典STHLM3人群诊断研究(2012年5月28日至2014年12月30日),随机选取976名50-69岁参与者,数字化6682张穿刺活检切片,另加93名外部男性的271张切片用于训练深度神经网络。
- 独立测试集来自STHLM3的246名男性共1631张活检,外部验证集来自73名男性共330张活检;另在23位国际泌尿病理学家单独分级的87张活检上评估分级性能。
主要发现
- 独立测试集中,AI区分良性(n=910)与恶性(n=721)活检核心的AUC为0·997(95% CI 0·994-0·999);外部验证集(良性n=108,恶性n=222)AUC为0·986(95% CI 0·972-0·996)。
- AI预测的癌长度与报告病理医生测量的癌长度相关性在独立测试集为0·96(95% CI 0·95-0·97),外部验证集为0·87(95% CI 0·84-0·90)。
- AI分配Gleason分级的平均成对kappa为0·62,处于专家病理学家对应值范围(0·60-0·73)之内。
临床怎么用
- AI系统有望通过减少对良性活检的评估和自动化测量阳性活检核心中的癌长度来减轻病理工作负荷。
- 具有专家级分级性能的AI系统可能提供第二意见、辅助标准化分级,并在缺乏病理专业知识的地区提供病理专业支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An increasing volume of prostate biopsies and a worldwide shortage of urological pathologists puts a strain on pathology departments. Additionally, the high intra-observer and inter-observer variability in grading can result in overtreatment and undertreatment of prostate cancer. To alleviate these problems, we aimed to develop an artificial intelligence (AI) system with clinically acceptable accuracy for prostate cancer detection, localisation, and Gleason grading. METHODS: We digitised 6682 slides from needle core biopsies from 976 randomly selected participants aged 50-69 in the Swedish prospective and population-based STHLM3 diagnostic study done between May 28, 2012, and Dec 30, 2014 (ISRCTN84445406), and another 271 from 93 men from outside the study. The resulting images were used to train deep neural networks for assessment of prostate biopsies. The networks were evaluated by predicting the presence, extent, and Gleason grade of malignant tissue for an independent test dataset comprising 1631 biopsies from 246 men from STHLM3 and an external validation dataset of 330 biopsies from 73 men. We also evaluated grading performance on 87 biopsies individually graded by 23 experienced urological pathologists from the International Society of Urological Pathology. We assessed discriminatory performance by receiver operating characteristics and tumour extent predictions by correlating predicted cancer length against measurements by the reporting pathologist. We quantified the concordance between grades assigned by the AI system and the expert urological pathologists using Cohen's kappa. FINDINGS: The AI achieved an area under the receiver operating characteristics curve of 0·997 (95% CI 0·994-0·999) for distinguishing between benign (n=910) and malignant (n=721) biopsy cores on the independent test dataset and 0·986 (0·972-0·996) on the external validation dataset (benign n=108, malignant n=222). The correlation between cancer length predicted by the AI and assigned by the reporting pathologist was 0·96 (95% CI 0·95-0·97) for the independent test dataset and 0·87 (0·84-0·90) for the external validation dataset. For assigning Gleason grades, the AI achieved a mean pairwise kappa of 0·62, which was within the range of the corresponding values for the expert pathologists (0·60-0·73). INTERPRETATION: An AI system can be trained to detect and grade cancer in prostate needle biopsy samples at a ranking comparable to that of international experts in prostate pathology. Clinical application could reduce pathology workload by reducing the assessment of benign biopsies and by automating the task of measuring cancer length in positive biopsy cores. An AI system with expert-level grading performance might contribute a second opinion, aid in standardising grading, and provide pathology expertise in parts of the world where it does not exist. FUNDING: Swedish Research Council, Swedish Cancer Society, Swedish eScience Research Center, EIT Health.
引用
- Ström P, Kartasalo K, Olsson H, et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncol. 2020. PMID: 31926806. doi:10.1016/S1470-2045(19)30738-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。